Screener
10x Genomics, Inc. TXG Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 6, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054491
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accounts payable | $20,694 | $12,733 |
| Accrued compensation and related benefits | 24,744 | 42,500 |
| Accrued expenses and other current liabilities | 30,377 | 39,971 |
| Deferred revenue | 23,610 | 23,902 |
| Operating lease liabilities | 12,015 | 10,985 |
| Contingent consideration, current | 7,069 | 23,363 |
| Total current liabilities | 118,509 | 153,454 |
| Contingent consideration, noncurrent | 2,991 | 1,237 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is 10x Genomics, Inc.'s deferred revenue?
- 10x Genomics, Inc. (TXG) reported deferred revenue of $23.61M in Q2 2026.
- How has 10x Genomics, Inc.'s deferred revenue changed year-over-year?
- 10x Genomics, Inc.'s deferred revenue increased by 10.1% year-over-year, from $21.45M to $23.61M.
- What is the long-term trend for 10x Genomics, Inc.'s deferred revenue?
- Over 5 years (2020 to 2025), 10x Genomics, Inc.'s deferred revenue has grown at a 39.8% compound annual growth rate (CAGR), from $4.47M to $23.9M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about 10x Genomics, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude